AU1295597A - Vitronectin receptor antagonists - Google Patents
Vitronectin receptor antagonistsInfo
- Publication number
- AU1295597A AU1295597A AU12955/97A AU1295597A AU1295597A AU 1295597 A AU1295597 A AU 1295597A AU 12955/97 A AU12955/97 A AU 12955/97A AU 1295597 A AU1295597 A AU 1295597A AU 1295597 A AU1295597 A AU 1295597A
- Authority
- AU
- Australia
- Prior art keywords
- amino
- ethyl
- pyridinyl
- mmol
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US936795P | 1995-12-29 | 1995-12-29 | |
| US009367 | 1995-12-29 | ||
| PCT/US1996/020327 WO1997024124A1 (en) | 1995-12-29 | 1996-12-20 | Vitronectin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU1295597A true AU1295597A (en) | 1997-07-28 |
Family
ID=21737218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU12955/97A Abandoned AU1295597A (en) | 1995-12-29 | 1996-12-20 | Vitronectin receptor antagonists |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6159964A (OSRAM) |
| EP (1) | EP0906103A1 (OSRAM) |
| JP (1) | JP2000502704A (OSRAM) |
| KR (1) | KR19990076877A (OSRAM) |
| CN (1) | CN1209063A (OSRAM) |
| AU (1) | AU1295597A (OSRAM) |
| BR (1) | BR9612381A (OSRAM) |
| CZ (1) | CZ203898A3 (OSRAM) |
| IL (1) | IL125030A0 (OSRAM) |
| NO (1) | NO983001L (OSRAM) |
| PL (1) | PL327626A1 (OSRAM) |
| TR (1) | TR199801254T2 (OSRAM) |
| WO (1) | WO1997024124A1 (OSRAM) |
| ZA (1) | ZA9610854B (OSRAM) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10504825A (ja) * | 1994-08-22 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | 二環式化合物 |
| JP2000502708A (ja) * | 1995-12-29 | 2000-03-07 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗物質 |
| WO1997037655A1 (en) * | 1996-04-10 | 1997-10-16 | Merck & Co., Inc. | αvβ3 ANTAGONISTS |
| US20030125317A1 (en) | 1996-10-02 | 2003-07-03 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| DE19653647A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
| DE19653645A1 (de) * | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
| US6218387B1 (en) | 1996-12-20 | 2001-04-17 | Hoechst Aktiengesellschaft | Vitronectin receptor anatagonists, their preparation and their use |
| US6482821B2 (en) | 1996-12-20 | 2002-11-19 | Hoechst Aktiengellschaft | Vitronectin receptor antagonists, their preparation and their use |
| CO4920232A1 (es) * | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin |
| JP2002510328A (ja) * | 1997-07-25 | 2002-04-02 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体アンタゴニスト |
| JP2002508323A (ja) * | 1997-12-17 | 2002-03-19 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
| WO1999043642A1 (en) | 1998-02-26 | 1999-09-02 | Celltech Therapeutics Limited | Phenylalanine derivatives as inhibitors of alpha4 integrins |
| AR015241A1 (es) * | 1998-03-10 | 2001-04-18 | Smithkline Beecham Corp | Antagonistas del receptor de vitronectina composicion farmaceutica que los contiene, procedimiento para su preparacion y su empleo para la fabricacion deun medicamento. |
| GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9812088D0 (en) | 1998-06-05 | 1998-08-05 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| SE9803773D0 (sv) * | 1998-11-05 | 1998-11-05 | Astra Pharma Prod | Compounds |
| GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| EP1150965A4 (en) | 1999-02-03 | 2002-05-15 | Merck & Co Inc | BENZAZEPINE DERIVATIVES AS ALPHA-V INTGRIN RECEPTOR ANTAGONISTS |
| KR20010093303A (ko) * | 1999-02-20 | 2001-10-27 | 플레믹 크리스티안 | β-알라닌 유도체 |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| WO2001007036A1 (en) | 1999-07-21 | 2001-02-01 | American Home Products Corporation | BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN |
| DE19939980A1 (de) | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Inhibitoren des Integrins alphavbeta¶3¶ |
| US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
| DE10028575A1 (de) | 2000-06-14 | 2002-03-14 | Basf Ag | Integrinliganden |
| GB9929988D0 (en) * | 1999-12-17 | 2000-02-09 | Celltech Therapeutics Ltd | Chemical compounds |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| EP1332132B1 (en) | 2000-04-17 | 2007-10-10 | UCB Pharma, S.A. | Enamine derivatives as cell adhesion molecules |
| US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
| US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
| DE10028402A1 (de) * | 2000-06-13 | 2001-12-20 | Merck Patent Gmbh | Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate |
| JP2004502762A (ja) | 2000-07-07 | 2004-01-29 | セルテック アール アンド ディ リミテッド | 二環性ヘテロ芳香環を含有するインテグリンアンタゴニストとしてのスクエア酸誘導体 |
| WO2002010136A1 (en) | 2000-08-02 | 2002-02-07 | Celltech R & D Limited | 3-substituted isoquinolin-1-yl derivatives |
| US20040058915A1 (en) * | 2000-08-29 | 2004-03-25 | Khanna Ish Kumar | Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists |
| BR0113671A (pt) * | 2000-08-30 | 2004-01-06 | Pharmacia Corp | Antagonistas de integrina alfa v beta 3 gem-substituìda |
| US6531494B1 (en) * | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
| US6472372B1 (en) * | 2000-12-06 | 2002-10-29 | Ortho-Mcneil Pharmaceuticals, Inc. | 6-O-Carbamoyl ketolide antibacterials |
| KR100376088B1 (ko) * | 2001-03-09 | 2003-03-28 | 주식회사 태평양 | 3-아미노프로필코질포스페이트 및 그의 염을 함유한미백화장료 조성물 |
| US20040136949A1 (en) | 2001-04-24 | 2004-07-15 | Matthias Grell | Combination therapy using anti-angiogenic agents and tnf alpha |
| KR101159061B1 (ko) | 2001-10-22 | 2012-06-22 | 더 스크립스 리서치 인스티튜트 | 항체 표적화 화합물 |
| NZ533282A (en) | 2001-12-05 | 2006-09-29 | Ortho Mcneil Pharm Inc | 6-O-Acyl ketolide derivatives of erythromycine useful as antibacterials |
| GB0130341D0 (en) * | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| ATE448312T1 (de) | 2003-09-26 | 2009-11-15 | Merck Serono Sa | Leitsequenzen zur verwendung bei der produktion von proteinen |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| JP2009512443A (ja) * | 2005-10-20 | 2009-03-26 | ザ スクリップス リサーチ インスチチュート | 免疫染色及び免疫標的化のためのＦｃ標識化 |
| WO2007079199A2 (en) * | 2005-12-30 | 2007-07-12 | Alantos Pharmaceuticals, Holding, Inc. | Substituted bis-amide metalloprotease inhibitors |
| EP2335733B1 (en) | 2006-01-18 | 2014-08-06 | Merck Patent GmbH | Specific therapy using integrin ligands for treating cancer |
| PT2101805E (pt) | 2007-01-18 | 2013-01-31 | Merck Patent Gmbh | Terapia específica e medicamento usando ligandos integrina para tratar o cancro |
| DE102007038250A1 (de) * | 2007-08-13 | 2009-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues Herstellverfahren |
| EP2730282A1 (en) | 2007-11-08 | 2014-05-14 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| EP2489656A1 (en) | 2007-12-21 | 2012-08-22 | Ligand Pharmaceuticals Inc. | Selective androgen receptor modulators (sarms) and uses thereof |
| EP2395992A2 (en) | 2009-02-10 | 2011-12-21 | The Scripps Research Institute | Chemically programmed vaccination |
| US8648066B2 (en) | 2009-05-22 | 2014-02-11 | Exelixis, Inc. | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture |
| EP2445534A2 (en) | 2009-05-25 | 2012-05-02 | Merck Patent GmbH | Continuous administration of cilengitide in cancer treatments |
| JP6649902B2 (ja) | 2014-05-30 | 2020-02-19 | ファイザー・インク | 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体 |
| RU2021109549A (ru) | 2014-08-29 | 2021-05-13 | Тес Фарма С.Р.Л. | ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ |
| MA45244A (fr) | 2016-06-13 | 2019-04-17 | Cancer Research Tech Ltd | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 |
| EP4147698A1 (en) | 2017-02-28 | 2023-03-15 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| BR112019017929A2 (pt) * | 2017-02-28 | 2020-05-19 | Morphic Therapeutic Inc | inibidores de integrina (alfa-v)(beta-6) |
| CN108558836A (zh) * | 2018-05-14 | 2018-09-21 | 东南大学 | 一类具有双重作用机制的dpp-4抑制剂及其用途 |
| ES3019404T3 (en) | 2018-08-29 | 2025-05-20 | Morphic Therapeutic Inc | Integrin inhibitors |
| CA3133929A1 (en) | 2019-04-19 | 2020-10-22 | Lin Zhi | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3450707A (en) * | 1966-12-13 | 1969-06-17 | Sterling Drug Inc | Certain 2-anilino-pyridine derivatives |
| US3627754A (en) * | 1970-05-13 | 1971-12-14 | Hoffmann La Roche | Process for preparing 7-lower alkanoyl benzodiazepines utilizing ceric salts |
| SG63579A1 (en) * | 1992-12-21 | 1999-03-30 | Smithkline Beecham Corp | Bicyclic fibrinogen antagonists |
| JPH10504807A (ja) * | 1994-06-29 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗剤 |
| ZA9610853B (en) * | 1995-12-29 | 1998-04-06 | Smithkline Beecham Corp | Processes and intermediates for preparing pharmaceuticals. |
-
1996
- 1996-12-20 JP JP9524453A patent/JP2000502704A/ja active Pending
- 1996-12-20 EP EP96943818A patent/EP0906103A1/en not_active Withdrawn
- 1996-12-20 KR KR1019980705004A patent/KR19990076877A/ko not_active Withdrawn
- 1996-12-20 WO PCT/US1996/020327 patent/WO1997024124A1/en not_active Ceased
- 1996-12-20 IL IL12503096A patent/IL125030A0/xx unknown
- 1996-12-20 CN CN96180114A patent/CN1209063A/zh active Pending
- 1996-12-20 AU AU12955/97A patent/AU1295597A/en not_active Abandoned
- 1996-12-20 BR BR9612381A patent/BR9612381A/pt unknown
- 1996-12-20 TR TR1998/01254T patent/TR199801254T2/xx unknown
- 1996-12-20 PL PL96327626A patent/PL327626A1/xx unknown
- 1996-12-20 US US09/091,937 patent/US6159964A/en not_active Expired - Fee Related
- 1996-12-20 CZ CZ982038A patent/CZ203898A3/cs unknown
- 1996-12-23 ZA ZA9610854A patent/ZA9610854B/xx unknown
-
1998
- 1998-06-26 NO NO983001A patent/NO983001L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000502704A (ja) | 2000-03-07 |
| KR19990076877A (ko) | 1999-10-25 |
| WO1997024124A1 (en) | 1997-07-10 |
| IL125030A0 (en) | 1999-01-26 |
| US6159964A (en) | 2000-12-12 |
| CN1209063A (zh) | 1999-02-24 |
| TR199801254T2 (xx) | 1998-10-21 |
| NO983001D0 (no) | 1998-06-26 |
| EP0906103A4 (OSRAM) | 1999-04-07 |
| BR9612381A (pt) | 1999-07-13 |
| PL327626A1 (en) | 1998-12-21 |
| EP0906103A1 (en) | 1999-04-07 |
| CZ203898A3 (cs) | 1999-03-17 |
| NO983001L (no) | 1998-08-26 |
| ZA9610854B (en) | 1998-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6159964A (en) | Vitronectin receptor antagonists | |
| WO1997024122A1 (en) | Vitronectin receptor antagonists | |
| US6239138B1 (en) | Vitronectin receptor antagonist | |
| CZ203698A3 (cs) | Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití | |
| EP0910563B1 (en) | Integrin receptor antagonists | |
| EP0767792A1 (en) | Vitronectin receptor antagonists | |
| JPH10504807A (ja) | ビトロネクチン受容体拮抗剤 | |
| US5977101A (en) | Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity | |
| JP2001514253A (ja) | インテグリンレセプターアンタゴニスト | |
| US6008213A (en) | Integrin receptor antagonists | |
| US20010034445A1 (en) | Vitronectin receptor antagonists | |
| CA2241755A1 (en) | Vitronectin receptor antagonists | |
| MXPA98005254A (en) | Vitronect receptor antagonists | |
| HK1019594B (en) | Integrin receptor antagonists | |
| PL191595B1 (pl) | Antagoniści receptorów integryny i kompozycje je zawierające |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |